Meeting
2024 ASCO Annual Meeting
Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 45-month (mo) follow-up from CheckMate 648.
Authors
Ian Chau
Royal Marsden Hospital, London & Surrey, United Kingdom
Ian Chau , Jaffer A. Ajani , Yuko Kitagawa , Jianming Xu , Lucjan S. Wyrwicz , Satoru Motoyama , Takashi Ogata , Hisato Kawakami , Chih-Hung Hsu , Antoine Adenis , Farid El Hajbi , Maria Di Bartolomeo , Maria Ignez Braghiroli , Eva Holtved , Mariela A. Blum Murphy , Raheel Nathani , Nan Hu , Yasuhiro Matsumura , Ken Kato , Yuichiro Doki
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03143153
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 4034)
DOI
10.1200/JCO.2024.42.16_suppl.4034
Abstract #
4034
Poster Bd #
14
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648.
First Author: Ian Chau
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
First Author: Kohei Shitara
Poster
2024 ASCO Gastrointestinal Cancers Symposium
First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 4-year (yr) follow-up.
First Author: Lin Shen
Poster
2023 ASCO Annual Meeting
Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.
First Author: Yelena Y. Janjigian